Why Women Get Recurrent Yeast Infections
Recurrent vulvovaginal candidiasis (RVVC), defined as three or more symptomatic episodes within 12 months, affects approximately 9% of women and results from a complex interplay of drug resistance, non-albicans Candida species, immune dysfunction, and potentially genetic predisposition—though the exact host factors remain poorly understood. 1
Primary Contributing Factors
Antifungal Resistance and Underdosing
The most clinically significant issue is unrecognized azole resistance at vaginal pH. Standard laboratory susceptibility testing occurs at pH 7, but the vaginal environment is pH 4. At this acidic pH, all antifungals demonstrate significantly higher minimum inhibitory concentrations (MICs), with terconazole showing up to 388-fold higher MIC against C. glabrata at pH 4 versus pH 7. 1 This means women may be receiving what appears to be adequate treatment based on lab testing, but the medication is functionally underdosed in the actual vaginal environment.
Non-Albicans Candida Species
Women infected with non-albicans Candida (particularly C. glabrata) experience significantly higher recurrence rates—66% versus 34% for C. albicans infections. 2 These species are frequently dose-dependent susceptible or outright resistant to fluconazole, yet standard empiric treatment assumes C. albicans as the causative organism. 3
Bacterial Vaginosis Connection
Recurrent bacterial vaginosis (BV) serves as a dominant trigger for RVVC. The dysbiosis from BV—not just the antibiotics used to treat it—compromises immune defenses and neutralizes vaginal yeast tolerance. This creates a proinflammatory environment that predisposes to consecutive VVC episodes post-treatment. The repeated antimicrobial exposure from treating recurrent BV also drives acquired fluconazole resistance in C. albicans isolates. 4
Host-Related Factors
While the evidence acknowledges these contribute to RVVC, the guideline explicitly states "little is known about host factors" 1:
- Genetic predisposition in idiopathic cases
- Compromised immune system integrity
- Uncontrolled diabetes
- Pregnancy and hormonal changes
- Immunosuppression
- Corticosteroid use 5
Clinical Implications and Pitfalls
The Maintenance Therapy Problem
Maintenance fluconazole improves quality of life in 96% of women, but it is "uncommonly curative"—more than 63% of women continue having infections after completing maintenance therapy. 1 This represents a suppressive rather than curative approach.
Diagnostic Accuracy Matters
Clinical microscopy has only 57.5% sensitivity compared to 90.7% for PCR testing. 1 Many women are being treated empirically without confirming the causative species, leading to inappropriate therapy when non-albicans species are present.
What to Evaluate
When a woman presents with recurrent infections, specifically assess:
- Confirm the diagnosis: Use fungal culture with species identification, not just clinical diagnosis
- Test at vaginal pH: Request susceptibility testing at pH 4 if available, or recognize standard testing may underestimate resistance
- Screen for BV: Recurrent BV may be the primary driver requiring concurrent management
- Identify the species: Non-albicans Candida requires different treatment strategies
- Review comorbidities: Diabetes control, immunosuppression, recent antibiotic use
- Age consideration: Highest prevalence occurs in women 25-34 years old (12%) 1
The Quality of Life Impact
RVVC causes profound morbidity beyond physical symptoms—low self-esteem, loss of confidence, difficulty with regular activities, sexual dysfunction, missed work days, and an estimated $4.7 billion in lost productivity annually in the US alone. 1 The psychological burden creates a cycle of stress and anxiety that compounds the condition.